EU Approves Johnson & Johnson’s IMAAVY® (nipocalimab) for Broad gMG Patients, Enabling Long-Term Disease Control
Johnson & Johnson Secures European Commission Approval for IMAAVY® (nipocalimab)—A Groundbreaking FcRn Blocker for Generalised Myasthenia Gravis In a landmark development for the treatment of generalized myasthenia gravis (gMG), Johnson…
Strand Therapeutics Welcomes Jeb Keiper to Its Board of Directors
Strand Therapeutics Strengthens Strategic Leadership with Appointment of Industry Veteran Jeb Keiper to Board of Directors Strand Therapeutics, a pioneering biotechnology company at the forefront of programmable mRNA therapeutics, has…
Latus Bio Receives IND Clearance and Key FDA Designations for LTS-101 in CLN2 Disease
Latus Bio Achieves Major Regulatory Milestone with IND Clearance and Triple FDA Designations for LTS-101 in CLN2 Disease Latus Bio, Inc., a clinical-stage biotechnology company at the forefront of adeno-associated…
AdvanCell Launches Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer
AdvanCell Launches Pivotal Phase 2 Expansion Trial of ADVC001, a First-in-Class Targeted Alpha Therapy for Metastatic Prostate Cancer AdvanCell, a clinical-stage radiopharmaceutical company at the forefront of developing next-generation targeted…
Samsung Bioepis Introduces Denosumab Biosimilars OBODENCE™ and XBRYK™ to European Market
Samsung Bioepis Launches Denosumab Biosimilars OBODENCE™ and XBRYK™ in Europe to Improve Access and Patient Outcomes Samsung Bioepis Co., Ltd., a global biopharmaceutical company recognized for its innovative work in…
Janux Reports Promising Phase 1 Results for JANX007 in mCRPC
Janux Therapeutics Reports Encouraging Interim Phase 1 Data for JANX007 in mCRPC, Highlighting Strong Efficacy and Manageable Safety Profile Janux Therapeutics, Inc. a clinical-stage biopharmaceutical company pioneering novel immunotherapies through…
AltPep Shows SOBIN-AD Peptide Improves Alzheimer’s Behavior in Preclinical Study at CTAD 2025
AltPep Corporation Presents New Preclinical Data Demonstrating SOBIN-AD Peptide Improves Cognition in Early and Symptomatic Alzheimer’s Disease Models at CTAD 2025 AltPep Corporation, a privately held biotechnology company dedicated to…
Cellares Names Ali Soleymannezhad as CCO to Drive Global Expansion and IPO Prep
Cellares Appoints Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion and Drive Cell Therapy Access Cellares, the pioneering Integrated Development and Manufacturing Organization (IDMO) transforming the cell…
Vistagen Announces Appointment of Nick Tressler as Chief Financial Officer
Vistagen Appoints Nick Tressler as Chief Financial Officer, Strengthening Leadership Team Amid Growth and Clinical Milestones Vistagen Therapeutics, Inc. a late clinical-stage biopharmaceutical company focused on pioneering neuroscience innovations through…
Octave Bioscience Partners with Quest Diagnostics to Expand MSDA Test Access
Octave Bioscience Partners with Quest Diagnostics to Expand Nationwide Access to MSDA Test Octave Bioscience, a commercial-stage precision care company at the forefront of redefining disease management in multiple sclerosis…
Omeros Corporation Finalizes Asset Purchase and License Agreement with Novo Nordisk for MASP-3 Inhibitor Zaltenibart
Omeros Corporation Announces Completion of Asset Purchase and License Agreement with Novo Nordisk for Zaltenibart a Late-Stage MASP-3 Inhibitor Omeros Corporation today announced the successful closing of its previously disclosed…
Mirum Pharmaceuticals Begins BLOOM Phase 2 Trial with First Patient Dosed Evaluating MRM-3379 for Fragile X Syndrome
Mirum Pharmaceuticals Enrolls First Participant in BLOOM Phase 2 Study Evaluating MRM-3379 for Fragile X Syndrome Mirum Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and delivering innovative therapies for…